Yes, celiac disease can cause osteoporosis and fractures. Active, undiagnosed celiac disease drives bone loss through at least four parallel mechanisms: malabsorption of calcium and vitamin D, chronic systemic inflammation that pushes bone resorption above bone formation, secondary hyperparathyroidism, and, in many adults, an autoimmune attack on bone tissue itself. Roughly 40 to 70 percent of adults newly diagnosed with celiac disease have low bone mineral density, and their fracture risk runs measurably above the general population. The damage is not permanent in most cases: a strict gluten-free diet plus targeted nutrient correction typically recovers bone density over 12 to 60 months.
The four mechanisms that strip bone in celiac disease
Bone is living tissue held in a constant tug-of-war between osteoblasts, which build it, and osteoclasts, which demolish it. Celiac disease tips that balance toward demolition through several independent routes at once. Understanding the mechanism matters because it explains why a bone-density scan alone can mislead, and why some patients fracture despite only mildly low readings.
The first route is simple malabsorption. The disease flattens the villi of the small intestine, the finger-like projections that absorb nutrients. Damaged duodenal and jejunal mucosa absorb calcium at roughly half the normal efficiency in untreated patients. Vitamin D absorption falls too, since it is fat-soluble and depends on healthy intestinal surface. Without adequate vitamin D, dietary calcium is absorbed at only 10 to 15 percent instead of the normal 30 percent.
The second route is inflammation. Active celiac disease keeps circulating cytokines such as TNF-alpha and IL-6 elevated. These molecules directly stimulate osteoclast maturation and suppress osteoblast activity. In plain terms: the immune system's chronic low-grade fire is chemically telling the body to eat its own skeleton. This inflammation-driven resorption can occur even in patients whose intestinal damage is patchy and whose nutrient levels look borderline normal.
The third route is secondary hyperparathyroidism. When calcium absorption drops, serum calcium dips. The parathyroid glands respond by releasing parathyroid hormone, which pulls calcium out of bone to keep blood levels stable. Chronically elevated PTH is a direct driver of cortical bone loss, particularly at the hip and wrist.
The fourth route is the least obvious and still the most debated: a direct autoimmune effect on bone. Several studies have found anti-tissue transglutaminase antibodies and other celiac autoantibodies binding to bone tissue, and some patients show low bone density disproportionate to their malabsorption. Whether this constitutes a true autoimmune osteopathy or simply a marker of disease activity remains an open question, and the evidence is not yet strong enough to treat it as established fact.
How common is low bone density and fracture in celiac patients?
The prevalence numbers are wide because they depend heavily on how bone density is measured and which population is sampled. Across the major studies, low bone mineral density (a T-score below -1.0, which includes both osteopenia and osteoporosis) appears in 40 to 70 percent of adults at diagnosis. Frank osteoporosis, defined as a T-score of -2.5 or lower, is found in roughly 15 to 30 percent of newly diagnosed adults.
The fracture signal is more clinically important than the density number. A large Swedish cohort study (Olsson and colleagues, 2008) tracked more than 13,000 celiac patients and found a 40 percent increase in hip fracture risk and a roughly 30 percent increase in any fracture compared with the general population. A 2014 meta-analysis by Heikkilä and colleagues put the overall fracture risk ratio at about 1.3, with the excess concentrated in the first years after diagnosis when intestinal damage is still active.
Men are affected more than many patients expect. Osteoporosis is often framed as a postmenopausal women's disease, but in celiac cohorts the male-to-female gap narrows sharply. Among adults with newly diagnosed celiac disease, low bone density is found at similar rates in men and women, and men show a comparatively larger deficit because their baseline bone density is higher. This is one of the more counterintuitive findings in the field and a reason not to dismiss bone risk in male patients.
Timing of diagnosis also matters. Patients diagnosed in childhood, before the growth spurt ends, often reach normal peak bone mass once treated. Patients diagnosed after peak bone mass is set, typically age 25 to 30, can recover density but only partially close the gap if the disease went active for a decade or more. This is why the interval from symptom onset to diagnosis, which averages 6 to 10 years in adults, is itself a bone risk factor.
Bone loss timeline from exposure to recovery
The time course of bone loss and recovery is one of the most useful things a patient can understand. Bone loss in celiac disease does not happen overnight, and recovery is not instant either. The table below lays out the typical pattern for an adult diagnosed after a long undiagnosed period.
| Timepoint | Typical bone mineral density change | Mechanism | What it means practically |
|---|---|---|---|
| 0 to 2 years of active undiagnosed disease | Mild decline, often subclinical | Early malabsorption, minimal inflammation | Rarely detected; DXA not usually done |
| 2 to 5 years active | T-score often drops toward -1.0 to -1.5 | Calcium/vitamin D malabsorption plus rising PTH | Osteopenia becomes likely |
| 5 to 10 years active | T-score often reaches -1.5 to -2.5 | Chronic inflammation and secondary hyperparathyroidism | Osteoporosis risk climbs steeply |
| At diagnosis | 40 to 70 percent have T-score below -1.0 | All four mechanisms active | Baseline DXA is recommended |
| 12 months gluten-free | Modest rise, often 1 to 3 percent at spine | Malabsorption resolves, inflammation falls | Small but measurable gain |
| 24 to 60 months gluten-free | Cumulative 3 to 10 percent gain at spine and hip | Continued remodeling, nutrient correction | Many reach normal or near-normal density |
Two caveats about this table. First, the percentages are averages across cohorts and vary widely between individuals. Second, the density gains assume strict adherence; patients who continue to consume gluten intermittently show little or no recovery. The typical pattern in non-adherent patients is continued decline, not stabilization.
The recovery timeline also interacts with age. A 30-year-old who goes gluten-free within a year of diagnosis may recover fully. A 65-year-old with established osteoporosis and ten years of active disease may recover density but still carry elevated fracture risk, because age-related bone loss continues alongside recovery.
Why bone density alone can mislead in celiac disease
This is the non-obvious caveat most thin explainers skip. A DXA scan measures areal bone mineral density, which is a two-dimensional projection of a three-dimensional structure. In celiac disease, bone loss is not uniform: cortical bone (the dense outer shell, as in the hip and wrist) is lost disproportionately because of the PTH-driven mechanism. Trabecular bone (the spongy interior, as in the spine) is lost too but at a different rate. That means a patient can have a spine T-score that looks reassuring while their hip cortex has thinned substantially.
The clinical consequence is that a single-site DXA reading can understate fracture risk. Professional guidance increasingly favors measuring both spine and hip, and interpreting the lowest T-score rather than an average. A patient with a spine T-score of -1.8 and a hip T-score of -2.6 has osteoporosis by the hip reading, and that hip number is the one that predicts hip fracture.
A second caveat concerns bone quality versus bone quantity. Celiac patients may have low bone density without proportionally high fracture risk in some cohorts, and vice versa. This is why fracture risk tools such as FRAX, which incorporate age, sex, prior fracture, and other clinical factors, are more useful than DXA alone for treatment decisions.
Variations and edge cases: who is at highest risk
Not every celiac patient carries the same bone risk. A few subgroups deserve specific attention because their risk is substantially higher than the average and their management should be more aggressive.
Postmenopausal women with celiac disease carry the highest absolute fracture risk, because they face celiac-driven loss plus estrogen-deficiency loss simultaneously. Men over 50 are the second-highest group, and are the most commonly under-screened. Patients with a history of prior fracture are at highest risk of a second fracture regardless of their DXA score.
Patients with persistent villous atrophy on follow-up biopsy despite a gluten-free diet are a critical but under-recognized group. Roughly 20 to 30 percent of patients on a self-reported gluten-free diet still show active mucosal damage on repeat biopsy. These patients continue to lose bone even though they believe they are treated, and their recovery timeline resets once adherence improves or inadvertent gluten exposure is identified.
Patients with concurrent autoimmune conditions, especially autoimmune thyroid disease and type 1 diabetes, face additive bone risk. Both conditions are overrepresented in celiac patients and both independently affect bone metabolism. This is why bone health assessment in celiac disease should not be limited to the gut.
Pediatric patients deserve separate mention. Children with untreated celiac disease often show low bone density for age, but their recovery after gluten withdrawal is typically complete and rapid, with catch-up growth and near-full density recovery within 12 to 24 months. The adult pattern of partial recovery does not apply to children diagnosed before puberty.
Common misconceptions about celiac disease and bone loss
The most widespread misconception is that a normal DXA scan rules out bone risk. As covered above, this is false; single-site scans and borderline readings can miss clinically meaningful risk, and fracture risk depends on more than the T-score.
A second misconception is that bone loss in celiac disease only happens in people with severe gastrointestinal symptoms. In reality, many patients diagnosed through screening, with minimal or no gut symptoms, still show low bone density. The "silent" presentations of celiac disease are often the ones with the longest diagnostic delay, and therefore the greatest cumulative bone loss.
A third misconception, and a dangerous one, is that calcium and vitamin D supplements alone will fix the bone problem. They help, but they do not address the underlying malabsorption as long as gluten exposure continues. Supplementation without a gluten-free diet is like patching a leaking roof without stopping the rain. The dietary change is the primary intervention; supplements are adjunctive.
A fourth misconception is that bone loss is irreversible. Many patients are told, incorrectly, that once they have osteoporosis they will always have it. In celiac disease specifically, density recovery after gluten withdrawal is well documented, and even patients with established osteoporosis can see meaningful gains over 24 to 60 months. Full normalization is not guaranteed, but improvement is the norm rather than the exception.
Red flags that warrant immediate bone evaluation
The following findings should prompt a bone density assessment and clinical review without waiting for routine follow-up:
- Any fragility fracture, meaning a fracture from a fall at standing height or lower, at any age
- A T-score of -2.5 or lower at any measured site, or a T-score of -1.5 or lower with a prior fracture
- A diagnosis of celiac disease in adulthood with more than five years of symptoms before diagnosis
- Persistent villous atrophy on repeat biopsy after 12 or more months of a gluten-free diet
- Concurrent autoimmune thyroid disease, type 1 diabetes, or inflammatory bowel disease
- Unexplained height loss of 1.5 inches or more, or new back pain suggesting vertebral fracture
These are not exhaustive, but they cover the highest-yield situations. Patients who recognize themselves in any of these categories should raise the issue explicitly with their clinician rather than assume their gastroenterologist has covered it.
What to actually do: practical bone protection in celiac disease
For patients with newly diagnosed celiac disease, the first step is a baseline DXA scan, ideally within the first three months of diagnosis. Guidelines from the American College of Gastroenterology and other professional bodies recommend bone density assessment at diagnosis in adults. If the scan is normal, repeat it every two to five years, or sooner if there are clinical changes.
The second step is a strict gluten-free diet, verified by follow-up. This means serology at 6 and 12 months (tissue transglutaminase IgA, with total IgA to rule out deficiency), and in many cases a repeat biopsy at 12 to 24 months if symptoms persist or serology does not normalize. Self-reported adherence is an unreliable measure; objective verification matters.
The third step is nutrient correction. Target a daily calcium intake of 1,000 to 1,200 mg from diet plus supplements, and vitamin D to a serum 25-hydroxyvitamin D level of at least 30 ng/mL. Some patients require higher vitamin D doses (2,000 to 4,000 IU daily) because of residual malabsorption, and levels should be rechecked at 3 months.
The fourth step is to consider pharmacologic therapy for osteoporosis when indicated. Bisphosphonates and other antiresorptives are appropriate for patients with a T-score of -2.5 or lower, or with a fragility fracture, and can be used alongside a gluten-free diet. There is no evidence that these drugs are less effective in celiac patients once malabsorption is corrected.
The fifth step is resistance and weight-bearing exercise, at least twice weekly, plus smoking cessation and moderation of alcohol intake. These are standard bone health measures but they carry particular weight in celiac patients, whose recovery window is finite.
Limitations of the evidence and what remains uncertain
The evidence base for celiac-related bone disease is strong on prevalence and fracture risk, moderate on recovery timelines, and weak on the direct autoimmune mechanism. The 40 to 70 percent low-density prevalence figure comes from heterogeneous cohorts using different DXA protocols, and some of the variation reflects measurement differences rather than true population differences. The fracture risk ratios, while consistent in direction, vary between 1.2 and 1.5 across studies depending on the cohort and follow-up period.
The recovery percentages in the timeline table are averages, and individual recovery can range from none to full normalization. There is no validated way to predict which patient will recover fully. This uncertainty is a reason to treat aggressively early rather than watch and wait.
The direct autoimmune bone effect remains the least settled area. Some studies show anti-tTG antibodies binding to bone, and some patients have low density without proportionate malabsorption, but the mechanistic evidence is not yet sufficient to change clinical management. It is a plausible hypothesis, not an established fact, and patients should treat claims of a proven autoimmune bone attack with appropriate skepticism.
The practical bottom line is that celiac disease is a well-established cause of osteoporosis and fractures, the mechanisms are well understood enough to guide treatment, and recovery is achievable in most patients with strict dietary adherence plus targeted nutrient and, when needed, pharmacologic therapy. The biggest risk is not the disease itself but the diagnostic delay and the under-screening of bone health in patients who already carry the diagnosis.